Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus and MMF after Fludarabine/TBI in HLA-Matched Family Donor SCT
NCT00304720Phase 2Unknown
- Sponsor
- Colorado Blood Cancer Institute
- Start
- Mar 2004
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tacrolimus and mycophenolate mofetil in multiple myeloma (MM), lymphoma, acute myeloid leukemia (AML) and 6 more, sponsored by Colorado Blood Cancer Institute. Primary endpoints: Day 100 mortality and Incidence of grade II-IV acute Graft-Versus-Host Disease at 100 days. Status: unknown.
02
Drugs
tacrolimusmycophenolate mofetil
03
Conditions
multiple myeloma (MM)lymphomaacute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00304720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00304720.